Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Dr. Arkady Mandel said
View:
Post by Sosak1 on Jun 21, 2022 8:13am

Dr. Arkady Mandel said

 Based on the strength of the clinical data collected and the consistently high safety and efficacy profile of Theralase(TM)'s PDT, I am confident that TLD-1433-based therapy has the potential to become the next gold-standard in the treatment of BCG-Unresponsive patients."
Comment by Legit62 on Jun 21, 2022 8:43am
I would also think we may get some new data before AGM, Like SF said, all pertinant info has to be made public prior to any release to shareholders, so we may see something very positive next week IMO
Comment by chry200030 on Jun 21, 2022 9:02am
WOW. excellent. We should rock and rol today.!
Comment by StevenBirch on Jun 21, 2022 9:26am
Looks like have found their stride again with a surprise news release. We already knew this but I liked these comments from Dr. Kulkarni, "a difficult patient population to treat" and "many also failed other investigational therapies prior to being treated with Theralase's PDT". Looking forward to the next few weeks/months.
Comment by CancerSlayer on Jun 21, 2022 3:41pm
  Would be interesting to know precisely how many patients received more than one drug therapy (i.e. more than BCG alone) prior to our ACT...& not referring to just your routine chemo, but to actual failed "investigational" therapies.  Would also be helpful to know why these "investigational" therapies failed (poor efficacy, increased side effects, not patient ...more  
Comment by ScienceFirst on Jun 21, 2022 3:45pm
CancerSlayer ... For the Ph. 1b, you have all this detail in the latest paper published.  See the link in this morning news.
Comment by BlueFranky on Jun 21, 2022 3:58pm
Excellent post Slayer - thank you!
Comment by 99942Apophis on Jun 21, 2022 5:00pm
CancerSlayer as you are aware I can barely get around in medical vernacular however you wrote  The key to a durable response/cure for any solid tumor imo has to involve not only a robust cancer cell kill rate, but also a long-lasting protective immunity...for some, inducing the latter may require a form of cancer vaccine (i.e. serial boosters) or a combo treatment that engenders a more ...more  
Comment by CancerSlayer on Jun 21, 2022 9:59pm
  Sorry for the late response...busy day today.  You raise an excellent point Apophis that unfortunately doesn't have a clear answer.  Assuming there are enough cancer cells destroyed, any treatment will generally induce an anticancer immune response (just as BCG does).  However, it would be very difficult to quantify how much a particular prior therapy would impact a ...more  
Comment by 99942Apophis on Jun 22, 2022 7:16am
Thanks CancerSlayer your medical education clears many of my questions and my ignorance in that field, my medical knowledge is from watching the movie Dr. Frankenstein lol.
Comment by Infinity on Jun 22, 2022 8:07am
Thank you Cancer Slayer for explaining the difficulty in the different types of treatments and immune system's responses.   Very precise and easy to understand.   I gather that 1. PDT developed by our little company offers a very viable treatment if not a complete cure.  2. The PDT can be repeated for certain patients who do not respond as well to the initial treatment ...more  
Comment by Lesalpes29 on Jun 22, 2022 8:43am
Not much interest for this kind of stock in a bear market maybe? News on BTD and deal with a big pharma will solve ower penny stock status I hope!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250